 Drug resistance and multidrug resistance modulators
专利摘要:
The present invention relates to drugs of the formula (C) and complex drug resistance modulators and pharmaceutically acceptable salts or solvent compounds thereof and their use in the preparation of pharmaceutical compositions. The present invention also relates to methods of treating drug and combination drug resistance in various diseases using the compounds of the present invention. The present invention also relates to methods for increasing the oral bioavailability of a drug and the bioavailability of the drug to the brain using the compounds of the present invention. <Formula C> Wherein Z is selected from the group consisting of -S-, -S (O) w -and -CH 2- , wherein w is 1 or 2. 公开号:KR20000057157A 申请号:KR1019990704442 申请日:1997-06-12 公开日:2000-09-15 发明作者:줄리안 에스. 크로인；브라이언 에이치. 노만 申请人:피터 지. 스트링거；일라이 릴리 앤드 캄파니； IPC主号:
专利说明:
Drug Resistance and Multidrug Resistance Modulators Among the problems faced with certain types of drug therapies, including cancer chemotherapy and malaria drug therapy, are resistant to treatment regimens. Tolerance means, for example, a cancer tumor that initially responds well to the drug (s) subsequently develops resistance to the drug (s) and stops responding. Drug resistance is a name given for a situation in which a disease (eg malaria or cancer) does not respond to drug (s) treatment. Drug resistance can be inherent, which means that the disease stops responding to previously responding drug (s). Combination drug resistance is associated with one or more functional and / or structurally unrelated drugs. It is a specific type of drug resistance characterized by the cross resistance of the disease. Combination drug resistance in the field of cancer is described in Detoxification Mechanisms and Tumor Cell Resistance to anticancer Drugs, by Kuzmich and Tew, especially in Section The "The Multidrug-Resistant Phenotype (MDR)," Medical Research Reviews, Vol ;. 11, No. 2, 185-217, (section 임 is pages 208-213) (1991), and "Multidrug Resistance and Chemosensitization: Therapeutic Implications for Cancer Chemotheraphy," by Georges, Sharom and Ling, Advances in Pharmacology, Vol. 21, 185-220 (1990). Drug and combination drug resistance typically involve the combination of a drug suitable for the treatment of a disease and a compound known as a drug resistance modulator or a combination drug resistance modulator. Drug and combination drug resistance modulators work through a variety of mechanisms to enable drug (s) suitable for treating a disease to begin and / or continue to function as a therapeutic agent. One known mechanism by which certain drugs and combination drug resistance modulators function is called various drug resistance 1 protein (MDR1), polyhedral glycoprotein (P-glycoprotein), Pgp or P170 (referred to as P-glycoprotein). To be interacted with). P-glycoproteins are endogenous in cell membranes, including certain drug resistant cells, complex drug resistant tumor cells, gastrointestinal cells and endothelial cells that form the blood brain barrier. P-glycoprotein acts as an outflow pump to cells. Undesirably, certain substances, including drug treatment for various diseases, come out of the cells by P-glycoprotein before they affect the cells. Drugs and combination drug resistance modulators interact with P-glycoproteins. This interaction makes it possible to prolong the effect by allowing therapeutic drugs to enter and remain in the cell by interfering with the action of the P-glycoprotein "drug outflow pump". In addition to inhibiting the release of several drugs from tumor cells, drugs and complex drug resistance modulators that interact with P-glycoproteins also function to increase the oral bioavailability of nutrients or drugs, Affected by its action with P-glycoprotein. Oral bioavailability refers to the ability of a drug to be administered orally and delivered through the gastrointestinal tract to enter the bloodstream. Drug or complex drug resistance modulators that interact with P-glycoprotein increase oral bioavailability of the drug or nutrient by interfering with the outflow pump action of P-glycoprotein. P-glycoprotein is believed to be present on both sides of the endothelial cell layer of capillary tubes of the brain. This capillary tube functions physiologically as the blood brain barrier. The blood brain gate is believed to limit the influx of many different kinds of compounds, including drugs entering the brain where the site of action is inside the brain. Certain drugs and complex drug resistance modulators that interact with P-glycoproteins also have the ability to interact with P-glycoproteins, increasing the bioavailability of the drug to the brain by disrupting the outflow pump action of P-glycoproteins in drug treatment. Can be. These disturbances allow more therapeutic drugs to enter the brain through the blood brain barrier and be present there. Certain drugs or combination drug resistance modulators that interact with P-glycoproteins are known. Examples include verapamil (calcium channel blockers that have been shown to lower blood pressure and are effective in the treatment of drug-resistant malaria in vitro), certain steroids, trifluoroperazines (specific nervous system drugs), bindolins and reserpin (Α-2 blockade with central nervous system properties). US Pat. No. 5,112,817 to Fukazawa et al. Discloses certain quinoline derivatives useful for the treatment of complex drug resistance in cancer. One of the initially promising active agents, MS-073, was found to be active in vitro tests. However, MS-073 exhibits insufficient oral bioavailability and has been found to have poor solubility problems upon dissolution. Other compounds of this class, such as the biphenylmethylcarbonyl derivative MS-209, have better stability and oral bioavailability, but have been found to be administered in larger amounts to be effective as complex drug resistance modulators. lost. PCT International Application No. PCT / US94 / 04215 (WO 94/24107) discloses 10,11-cyclopropyldibenzosuberan derivatives useful as complex drug resistance modulators. There is a need to develop additional compounds that interact with P-glycoproteins to interact with P-glycoproteins and act as drugs and combination drug resistance modulators to treat drug and combination drug resistance in various diseases. Additional compounds that interact with the P-glycoprotein may also act to increase the bioavailability of the drug (s) into the brain and / or to increase the oral bioavailability of the drug (s). need. The present invention relates to the field of synthetic organic chemistry. In particular, the present invention relates to pharmaceutical compounds useful in the field of drug resistance and complex drug resistance. A first aspect of the invention is a compound of formula (C), and a pharmaceutically acceptable salt or solvent compound thereof. In the formula, R 1 and R 2 are independently hydrogen or halo, A is -CH 2 -CH 2 -or CH 2 -CHR 4- (CH 2 ) n (here, n is 1 or 2, R 4 is -H, -OH or -R 5 , -R 5 is or ego, -R 6 is C 1 -C 6 alkyl or ego, m is 1, 2, 3, 4, 5 or 6, R 7 is —H or C 1 -C 6 alkyl) When A is CH 2 -CHR 4- (CH 2 ) n , A and Z are arranged as CH 2 -CHR 4- (CH 2 ) n -Z, Z is selected from the group consisting of -S-, -S (O) w -and -CH 2- , wherein w is 1 or 2, R 3 is aryl being jangiyi selected from the group consisting of phenyl, substituted phenyl, heteroaryl, substituted heteroaryl, polynuclear aryl and substituted polynuclear aryl, with the proviso that Z is connected to the R 3 ring carbon atoms in the R 3. The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient together with a compound of formula (C) or a salt or solvent compound thereof. The present invention further provides a pharmaceutical composition containing a compound of formula (C) or a salt or solvent compound thereof and a pharmaceutically acceptable carrier, diluent or excipient together with a cancer therapeutic drug. The present invention further provides a pharmaceutical composition comprising a compound of formula (C) or a salt or solvent compound thereof and a pharmaceutically acceptable carrier, diluent or excipient together with a malaria therapeutic drug. The present invention further provides a method of treating a drug resistant disease comprising administering a resistance modulating amount of a compound of formula (C) or a salt or a solvent compound thereof and an effective amount of a drug for treating a drug resistant disease to a mammal in need thereof. To provide. The present invention further provides a modified dose of a compound of formula (C) or a salt or solvent compound thereof, and an effective amount of a therapeutic drug for a combination drug resistant disease, comprising administering a drug to a mammal in need thereof. Provide a method of treatment. The invention further comprises combining a therapeutically effective amount of a drug with a compound of formula (C), or a salt or solvent thereof, in an amount sufficient to allow the drug to enter the brain through the blood brain barrier. Provided are methods for enhancing the bioavailability of a drug in the brain, including administering. The present invention further provides a combination of a therapeutically effective amount of a drug and an amount of a compound of formula (C) or a salt or solvent thereof sufficient to allow the drug to enter the bloodstream through the gastrointestinal tract to a mammal in need thereof. It provides a method for enhancing oral bioavailability of a drug, including. The following definitions are set forth for purposes of illustration and define the meaning and scope of the various terms used to describe the invention. The term "alkyl" refers to a fully saturated monovalent moiety which may be straight or branched, containing only carbon and hydrogen and having the indicated number of carbon atoms. Examples of the term include, but are not limited to, residues of 1 to 6 carbon atoms, for example methyl, ethyl, propyl, t-butyl, pentyl, isopentyl. C 1 -C 4 alkyl refers to an alkyl group having 1 to 4 carbon atoms. The term "alkanediyl" refers to a fully saturated divalent straight chain moiety containing only carbon and hydrogen and having the indicated number of carbon atoms. Alkanediyl is derived by removing hydrogen from two terminal carbon angles in the alkane chain. Examples of this term include compounds having 1 to 6 carbon atoms, for example methanediyl (aka methylene), ethane-1,2-diyl, propane-1,3-diyl, butane-1,4-diyl , Pentane-1,5-diyl and hexane-1,6-diyl, but are not limited thereto. C 1 -C 4 alkanediyl refers to alkanediyl having 1 to 4 carbon atoms. The term "-oxy (C 1 -C 6 alkanoyl)" is a formula (Wherein R 20 is C 1 -C 6 alkyl). The term "-oxycarbonyl (C 1 -C 6 alkanoxy)" is a formula (Wherein R 20 is C 1 -C 6 alkyl). The term "-oxycarbonyl (C 1 -C 6 alkanediyl) carboxy" is a formula (Wherein m is 1, 2, 3, 4, 5 or 6). The term "-oxycarbonyl (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy)" is a formula In which m and R 20 are as defined above. The term "-oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxy" is a formula In which m is as defined above. The term "-oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy)" is a formula In which m and R 20 are as defined above. The term "aromatic" refers to an unsaturated planar ring containing at least one group of atoms in a cyclic arrangement containing an unlocalized π electron cloud above and below the plane of the atom. In addition, the π electron cloud in each ring must contain a total of (4e + 2) (where e is any positive integer). The term "aryl" refers to monovalent aromatic ring (s). The aryl ring may be optionally substituted. The term “heteroaromatic ring” refers to an aromatic ring containing 3 to 5 carbon atoms and 1 to 3 heteroatoms, wherein the heteroatom (s) are each selected from the group consisting of nitrogen, oxygen and sulfur, There are only three carbon atoms in the ring and two or more must each be selected from heteroatoms. The term "heteroaryl" refers to a monovalent heteroaromatic ring. Examples of heteroaryl residues include, but are not limited to, structures such as: Heteroaryl rings may be optionally substituted. Multinuclear aryl moieties are monovalent aromatic multiple ring fused structures. If the rings are all carbocyclic, these multinuclear aryl moieties contain 2 to 4 fused rings. If more than one heterocyclic ring is present, the multinuclear aryl moiety contains two fused rings. Multinuclear aryl moieties include A) phenyl fused to one to three benzene rings, B) heteroaryl fused to a benzene ring, C) phenyl fused to a heteroaromatic ring, and D) heteroaryl fused to a heteroaromatic ring. have. Multinuclear aryl moieties may be optionally substituted. Examples of the "phenyl substituted with 1 to 3 benzene rings" structures include, but are not limited to the following formulas. Straight bonds leading to dashed bonds present in the above formula indicate that the bond can be connected to any carbon that can be used in any ring where the straight-dotted line intersects. These conventions will be used for these structures and all other fused ring structures present at various positions for bonding. Examples of "heteroaryl fused to benzene ring" and "phenyl fused to heteroaromatic ring" include, but are not limited to, a structure as follows. Whether the structure is "heteroaryl fused to benzene ring" or "phenyl fused to heteroaromatic ring" depends on the R 3 ring bond attached to the Z component of formula (C). Examples of "heteroaryl fused with a heteroaromatic ring" include, but are not limited to, the following formulas. The term "substituted" means that one to three hydrogens bonded to carbon in the ring are C 1 -C 4 alkyl, bromo, chloro, fluoro, iodo, cyano, amino, nitro, trifluoro Means being replaced with a plurality of residues each selected from the group consisting of methyl, difluoromethoxy and hydroxyl, wherein the substituted structures are arranged in stereo conformation to any one to form a stable structure and react as described herein. Should be The term "fused" refers to a ring that shares a pair of carbon atoms. The term "halo" refers to pullo, bromo, chloro and iodo. The term "optionally" with respect to a substituent means that the substituent is present or may not be present if indicated. A "pharmaceutically acceptable salt" can be any non-toxic salt derived from an inorganic or organic acid suitable for administration with a drug. Salts include inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid (given as sulfate and hydrogen sulphate as acetates), nitric acid, phosphoric acid, etc.) and organic acids (e.g. acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid) , Malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, salicylic acid, p-toluenesulfonic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, lactic acid, o -(4-hydroxybenzoyl) benzoic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo [2.2. 2] oct-2-ene-1-carboxylic acid, glycoheptonic acid, 4,4'-methylenebis (3-hydroxy-2-naphthoic acid), 3-phenylpropionic acid, trimethylacetic acid, t-butylacetic acid Lauryl sulfate, glucuronic acid, glutamic acid, 3-hydroxy-2-naphthoic acid, stearic acid, Cornic acid). "Pharmaceutically acceptable solvent compound" refers to agglomerates of a compound of formula (C) with a solvent molecule. The solvent can be water or any conventional organic solvent. The term "in vivo utilization" refers to the extent and rate at which a drug or other substance becomes available for use in other crude in a mammal. The term "treatment" or "treat" means administering an appropriate therapeutic or prophylactic amount of a compound to a mammal. The term "effective amount" means a dosage sufficient to cause a positive change in the disease state to be treated. The term “positive change” can be readily determined by one skilled in the art, although the meaning may vary depending on the patient, the disease and the treatment performed. For example, an effective amount of tumor cell destruction may be an amount that reduces the size of a cancerous tumor or, if no decrease in tumor size occurs, an effective amount of tumor cell destruction may be an amount that reduces analgesic consumption in cancer patients. The term "complex administration" means that a disease therapeutic drug and a compound of formula (C) are awarded to a mammal. The drug and the compound of formula (C) may be awarded to the mammal at the same time or at different times. The term "drug resistance" refers to a situation in which the disease does not respond to the therapeutic drug (s). Drug resistance may be intrinsic to mean that the disease is never responsive to the drug (s), or it may be acquired to mean that the disease has stopped responding to the drug (s) previously reacted. "Compound drug resistance" is a specific type of drug resistance characterized by cross resistance of the disease to one or more functional and / or structurally unrelated drugs. Combination drug resistance can be either intrinsic or acquired. For compounds of formula (C), the preferred moieties for the various substituents are as follows. R 1 and R 2 are both halo, more preferably all fluoro, R 3 is quinolyl, substituted quinolyl, isoquinolyl, substituted isoquinolyl, indolyl, substituted indolyl, naphthyl, substituted naphthyl, A is CH 2 -CHR 4- (CH 2 ) n , wherein R 4 is preferably -OH and n is 1 or 2, Z is -S- or -CH 2- . Compounds of formula (C) exist in two isomeric configurations defined by the relationship of 10,11-cyclopropyl and 5-piperazinyl substituents on dibenzosuberan. The isomeric form is called “thin” if both the 10,11-cyclopropyl and 5-piperazinyl substituents are in the same direction (eg all up or all down) with respect to dibenzosuberan. The isomeric form is called “anti” when the 10,11-cyclopropyl and 5-piperazinyl substituents are in opposite directions (eg, one up and the other down) with respect to dibenzosuberan. In general, the drug / complex drug resistant activity of the compounds of formula (C) in the "anti" configuration has been found to be much better than the activities of the compounds of formula (C) in the "thin" configuration. Certain compounds of formula (C) will have an asymmetric center in the "A" component when R 4 is not hydrogen. This compound may exist in two stereoisomeric forms, namely (R)-and (S)-, or a mixture of these two stereoisomeric forms. Although certain stereoisomers have been disclosed and named, the present invention encompasses both the "anti" and "thin" arrangements, as well as the racemates and other forms thereof, as well as the (R)-and (S) -isomers in these arrangements. It is interpreted as. Thus, the (thin, anti) designation in the compound name means that each of the two stereoisomers are included as described as preferred compounds. Similarly, the (R, S) designation means that each of the two stereoisomers at the indicated positions is included in what is described as the preferred compound. Preferred compounds of the present invention 1a) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-yl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1b) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-yl} quinoline or Pharmaceutically acceptable salt or solvent compounds thereof; 1c) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) pent-5-yl} quinoline or Pharmaceutically acceptable salt or solvent compounds thereof; 1d) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylthio} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1e) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylthio} Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1f) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylthio} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1 g) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfinyl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1h) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfinyl} Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1i) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfinyl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1j) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfonyl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1k) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfonyl} Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1l) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfonyl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1 m) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1n) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxypent-5yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1o) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylthio} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1p) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylthio} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1q) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfinyl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1r) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfinyl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1s) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfonyl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1t) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfonyl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1u) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) but-4yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1v) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) pent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1w) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) but-4-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1x) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) pent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1y) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) but-4-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1z) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1aa) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxybut-4-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1bb) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxypent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1 cc) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carboxybut-4-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1dd) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2a) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-yl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2b) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-yl} isoquinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 2c) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) pent-5-yl} isoquinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 2d) (thin, -anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylthio} Isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2e) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylthio} Isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2f) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylthio} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2 g) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfinyl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2h) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfinyl} Isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2i) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfinyl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2j) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfonyl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2k) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfonyl} Isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 21) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfonyl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2m) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2n) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxypent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2o) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylthio} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2p) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylthio} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2q) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfinyl} -isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2r) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfinyl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2s) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfonyl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2t) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfonyl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2u) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) but-4yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2v) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) pent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2w) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) but-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2x) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) pent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2y) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) but-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2z) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2aa) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxybut-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2bb) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S) oxy Carbonyloxy (C 1 -C 6 alkanediyl) carboxypent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2 cc) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carboxybut-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2dd) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 3a) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-yl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3b) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-yl} indole or Pharmaceutically acceptable salt or solvent compounds thereof; 3c) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) pent-5-yl} indole or Pharmaceutically acceptable salt or solvent compounds thereof; 3d) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylthio} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3e) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylthio} Indole or a pharmaceutically acceptable salt or solvent compound thereof; 3f) (thin, anti) -4- {1-4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylthio} indole or Pharmaceutically acceptable salt or solvent compounds thereof; 3 g) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfinyl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3h) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfinyl} Indole or a pharmaceutically acceptable salt or solvent compound thereof; 3i) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfinyl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3j) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfonyl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3k) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfonyl} Indole or a pharmaceutically acceptable salt or solvent compound thereof; 31) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfonyl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3m) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3n) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxypent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3o) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylthio} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3p) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylthio} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3q) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfinyl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3r) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfinyl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3s) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfonyl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3t) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfonyl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3u) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) but-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3v) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) pent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3w) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) but-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3x) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) pent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3y) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) but-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3z) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3aa) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxybut-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3bb) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxypent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3 cc) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carboxybut-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3dd) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 4a) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-yl} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4b) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-yl} naphthalene or Pharmaceutically acceptable salt or solvent compounds thereof; 4c) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) pent-5-yl} naphthalene or Pharmaceutically acceptable salt or solvent compounds thereof; 4d) (thin, -anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylthio} Naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4e) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylthio} Naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4f) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylthio} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4 g) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfinyl} nat Talene or a pharmaceutically acceptable salt or solvent compound thereof; 4h) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfinyl} Naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4i) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfinyl} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4j) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfonyl} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4k) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfonyl} Naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 41) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfonyl} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4m) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4n) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxypent-5yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4o) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylthio} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4p) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylthio} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4q) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfinyl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4r) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfinyl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4s) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfonyl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4t) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfonyl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4u) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) but-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4v) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) pent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4w) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) but-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4x) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) pent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4y) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) but-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4z) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4aa) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxybut-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4bb) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxypent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4 cc) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carboxybut-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4dd) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof, and mixtures thereof. Preferred compounds of the present invention are compounds of formula (CS) <Formula CS> Wherein R 1 , R 2 , R 3 , A and Z all have the same definition as defined above. Another preferred compound of the invention is anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2-hydroxybutyrate 4-yl} quinoline is a compound of formula (C1) which is a mixture of trihydrochloride salts of the 2 (R) and 2 (S) stereoisomers. The mixture is named anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2- (R, S)- Hydroxybut-4-yl} quinoline 3HCl. Another preferred compound is anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R) -hydroxyprop P-3-ylthio} quinoline.3HCl. The compound of formula (C2). Compounds of formula (C) may be prepared by reacting 10,11- (optionally mono or dihalo) cyclopropyldibenzosuber-5-ylpiperazine of formula (A). Wherein R 1 and R 2 may be hydrogen or halo. To prepare a compound of formula (C) wherein Z is -CH 2- , A is (-CH 2- ) d and d is 2, 3 or 4, the compound of formula (A) React with aryl- (C 3 -C 5 ) alkanediyl-halide. R 3- (CH 2 ) c -X Wherein R 3 is as defined above, c is 3, 4 or 5 and X is halo. Compound 10,11- (optionally mono or dihalo) cyclopropyldibenzosuber-5-ylpiperazine of Formula (A) is disclosed in PCT Patent Application PCT / US94 / 04215 (Publication No. WO 94/24107). It can be prepared using the techniques described on page -12. For simplicity, this synthesis can be accomplished using the following four step process. 1) Dibenzosuberenone (Aldrich Chemical Company, Milwaukee, WI) is converted to 10,11- (optionally mono or dihalo) cyclopropyldibenzosubernon by reacting with a suitable acetate reagent. Suitable acetate reagents are selected for the ability to add the desired substituents for R 1 and R 2 to the cyclopropyl ring, for example R 1 and R 2 using sodium chlorodifluoro-acetate or methyl trichloroacetate Let all be chloro and use ethyl trifluoroacetate to make both R 1 and R 2 fluoro. 2) 10,11- (optionally mono or dihalo) cyclopropyldibenzosubernone is reacted with a reducing agent to convert the 5-ketone functional groups to 5-alcohol functional groups. 3) Halogenated 10,11- (optionally mono or dihalo) cyclopropyldibenzosuber-5-ol at position 5 and then reacted with 1-piperazinecarboxaldehyde to react the Induces nuclear substitution to form a mixture of (thin, anti) -1-((10,11-optionally mono or dihalo) cyclopropyldibenzosuber-5-yl) -4-formyl-piperazine . The mixture can be separated into the thin and anti component by techniques known in the art, for example by chromatography. 4) Since the selected scene- or anti-1-((10,11-optionally mono or dihalo) cyclopropyldibenzosuber-5-yl) -4-formyl-piperazine can degrade the formyl group Reflux in a solvent for a sufficient time to form the corresponding 1-((10,11-optionally mono or dihalo) cyclopropyldibenzosuber-5-yl) piperazine of formula (A). The aryl- (C 3 -C 5 ) alkanediyl halide (s) of formula (B1) can be prepared by using standard techniques for adding alkyl halide chains to aromatic groups. The aromatic group is selected to obtain the desired R 3 aryl group and the alkyl portion of the alkyl halide is selected to obtain the desired number (3 to 5) of —CH 2 — groups for the Z and A components of the compound of formula (C). . Preferred halides for alkyl halides are iodides. Such synthesis is described in detail in US Pat. No. 5,112,817, which is incorporated herein by reference. After obtaining a compound of formula (B1) it is thermally reacted in a solvent with a compound of formula (A) as described in US Pat. Z is -S-, A is (-CH 2- ) d , and d is a compound of formula (A) for preparing a compound of formula (C) as defined above React with (C 2 -C 4 ) alkanediyl halides. R 3 -S- (CH 2 ) p -X Wherein R 3 and X are as defined above and p is 2, 3 or 4. Preparation of Thioaryl- (C 2 -C 4 ) alkanediyl halide (s) of Formula (B2) by the use of known techniques for the addition of alkylhalide chains to the sulfur atoms of the R 3 -SH thioacyl group can do. This addition is carried out by attaching the terminal carbon of the alkyl halide to the sulfur of the thioaryl group. Thioaryl groups are commercially available or can be synthesized using techniques known in the art, and this method of synthesis is the addition of sulfur atoms to the R 3 -I compound. After obtaining the compound of formula (B1), it is thermally reacted with the compound of formula (A) in a solvent. Z is -CH 2- , A is -CH 2 -CHR 4- (CH 2 ) n- , n is 1 or 2, and R 4 is -OH to prepare a compound of formula (C) The compound of A) is reacted with aryl- (C 2 -C 3 ) alkanediyl-epoxide of formula (B3). Wherein R 3 is as defined above and g is 2 or 3. The aryl- (C 2 -C 3 ) alkanediyl-epoxide (s) of formula (B3) is used to convert arylaldehyde to aryl- (C 2 -C 3 ) alkanediyl using standard techniques known in the art. It can be prepared by converting to ethoxide (s). The carbon number of the aldehyde chain is selected to obtain the desired number of -CH 2 -groups in the -ZA-component of formula (C), and the aryl ring is selected to obtain the desired R 3 component of formula (C). Arylaldehydes of the formula R 3- (CH 2 ) g -CHO, wherein g is 2 or 3, can be prepared by a number of methods known in the art. This method is R 3 - a 2-step transition to the aldehyde - R 3 of the halo compound. R 3 - the first step in the conversion of the aldehyde is hekeu (Heck) coupling using standard coupling reaction techniques, such as ring reactions described alkene - - R 3 of the halo compound, or an alkyne-acetal R 3-halo compound with coupling Ring reaction. Acetal functional groups to be. The carbon of the acetal functional group represented by * is the terminal carbon of the alkene or alkyne chain. For example, 1-propyne-3-dialkylacetal to be. The alkyl group in the acetal functional group is independently C 1 -C 6 alkyl. Preferred halo for the R 3 -halo compound is iodo. The alkenes or alkynes used in the alkene- or alkyne-acetal may be propene, propyne, butene or butyne. The choice of alkene or alkyne depends on the desired number of carbon atoms in the -ZA- component of the compound of formula (C). The Heck coupling reaction couples an alkene or alkyne chain to any terminal functional group or other terminal group for the haloaromatic compound using a palladium catalyst and a suitable base in a suitable nonreactive organic solvent such as acetalnitrile. Suitable bases are any suitable bases known in the heck palladium catalysis reaction technique, such as triethylamine. Similarly, a suitable solvent is any suitable non-reactive organic solvent such as acetonitrile. After the alkene- or alkyne-acetal moiety is coupled with the R 3 group, the double or triple bond is reduced to a single bond by hydrogenation using palladium on a suitable carbon catalyst. Acetal functional groups are converted to aldehyde functional groups by acid hydrolysis. After preparing the appropriate R 3 -aldehyde, it can be converted to R 3- (C 2 -C 3 ) alkanediyl-epoxide of formula (B3) by treating it with sodium hydride and sulfoxium or sulfonium iodide. . After obtaining a compound of formula (B3), it is thermally reacted with a compound of formula (A) in a solvent as described above. To prepare a compound of formula (C) wherein Z is -S-, A is -CH 2 -CHR 4- (CH 2 ) n , n is 1 or 2, and R 4 is -OH, ) Is reacted with thioaryl- (C 1 -C 2 ) alkanediyl-epoxide of formula (B4). Wherein R 3 is as defined above and t is 1 or 2. Thioaryl- (C 1 -C 2 ) alkanediyl-epoxide (s) of formula (B4) are prepared by converting a haloaryl compound to a thioaryl compound followed by coupling an alkanediyl-epoxide group to a thio compound. Can be prepared by forming a thioaryl- (C 1 -C 2 ) alkanediyl-epoxide. The haloaryl compound is preferably of formula R 3 -I. The conversion of the haloaryl compound to thioaryl can be carried out by reacting haloaryl with a suitable organolilium reagent such as t-butyllithium followed by addition of sulfur to the reaction. After the thioaryl compound is formed, it is reacted with a suitable reagent capable of attaching the (C 1 -C 2 ) -alkanediyl epoxide chain to sulfur bonded to the aryl ring to form a thioaryl- (C 1- C 2 ) to form alkanediyl-epoxide (s). Suitable reagents for this reaction are (2R)-(-)-glycidyl 3-nitrobenzenesulfonate. After obtaining a compound of formula (B4), it is thermally reacted with a compound of formula (A) in a solvent as defined above. When Z is -SO-, sulfur (-S-) which combines the -A- component of formula (C) with R 3 after preparing a compound of formula (C) is an oxidizing agent per equivalent of the compound of formula (C) Oxide to -SO- using 1 equivalent. Sulfur may be oxidized by the addition of a suitable oxidizing agent such as MCPBA (3-chloroperoxybenzoic acid) or Oxane (R) (potassium peroxymonosulfate, from EI DuPont de Nemours & Company) or sodium periodate. When Z is -SO 2 -The same method as for Z is -SO- is followed, except that 2 equivalents of oxidant per equivalent of formula (C) is used. Also, oxidation of -S- to -SO- or -SO 2 -may occur before the compound of formula (A) is coupled with the compound of formula (B2) or formula (B4). R 4 is R 6 is an acylation reaction using a standard technique known in the art after preparing a compound of formula (C) wherein R 4 is a hydroxy group to prepare a compound of formula (C) as defined above Let's do it. R 4 is R 6 is a compound of formula (C) wherein R 4 is a hydroxy group to prepare a compound of formula (C) as defined above and then the hydroxy group is prepared using standard techniques known in the art. Switch to Isolation and purification of the compounds and intermediates may be carried out if desired by any suitable separation or purification method such as, for example, filtration, extraction, crystallization, column chromatography, thin layer chromatography or thick layer chromatography or combinations of these methods. Compounds of formula (C) can be converted to the corresponding acid addition salts. Conversion is achieved by treatment with stoichiometric amounts of suitable acids, suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid (which provides sulfate and hydrogen sulfate as acetates), nitric acid, phosphoric acid and the like, and acetic acid, propionic acid, glycols Acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, salicylic acid, p-toluene-sulfonic acid, hexanoic acid, heptanoic acid, Cyclopentanepropionic acid, lactic acid, o- (4-hydroxy-benzoyl) benzoic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, camphorsulfonic acid , 4-methylbicyclo [2.2.0] oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis (3-hydroxy-2-naphtho) acid, 3-phenyl Propionic acid, trimethylacetic acid, t-butylacetic acid, lauryl sulfate, gluqu There are organic acids, such as acid, glutamic acid, 4,4'-methylenebis (3-hydroxy-2-naphthoic acid), stearic acid, non-acid. In the salt forming step of the present invention, the free base is usually dissolved in a polar organic solvent such as methanol or ethanol and the acid is added to water, methanol or ethanol. The temperature is maintained at 0 to 50 ° C. Corresponding salts may be spontaneously precipitated or obtained from less polar solvents or by evaporation of the solvent or by cooling the solution. In the vitrification step of the free base of formula (C) according to the invention the acid addition salts of the compounds of formula (C) are in excess of a suitable base, such as ammonia or sodium bicarbonate, usually in the presence of an aqueous solvent at a temperature of from 0 to 50 ° C. By treatment at can be decomposed into the corresponding free base. The free base is isolated by conventional methods such as extraction with organic solvents. The stoichiometric excess should be taken into account for the number of equivalents of acid bound by the base of formula (C). As described above, the present invention includes solvates of the compounds of formula (C) and pharmaceutically acceptable salts thereof. Specific compounds of the present invention or pharmaceutically acceptable salts thereof may form solvates with water or conventional organic solvents. Such solvates fall within the scope of the compounds of the present invention. <Industry availability> The compounds of the present invention are useful as drug resistance and complex drug resistance modulators. It is useful for treating drug resistance and complex drug resistance after resistance becomes clinically evident, and can also be administered early in drug therapy to improve drug activity from the beginning of drug administration before any clinical resistance becomes evident. The compounds of the present invention are particularly useful for the treatment of drug resistant and combination drug resistant cancer and drug resistant malaria. In addition, the compounds of the present invention are useful for improving oral bioavailability of drugs. In addition, the compounds of the present invention are useful for improving the bioavailability of drugs to the brain. As described above, the present invention includes a mixture of a compound of formula (C) or a pharmaceutically acceptable salt or solvate thereof. Preferred mixtures include at least one pair of enantiomer containing racemic mixtures. Such preferred mixtures as described above are anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2-hydroxybutyrate 4-yl} quinoline is a mixture of trihydrochloride salts of 2 (R) and 2 (S) enantiomers. When an in vitro test for complex drug resistance control is performed with a cancer chemotherapeutic drug, the compound is evaluated for its ability to demonstrate complex drug resistance control when administered in combination with a tumor cell destroyer. In vitro tests include cytotoxicity assays, which include CEM / VLB 100 (manufactured by Dr. William Beck of St. Jude's Research Hospital in Tennessee), in the presence of appropriate tumor cell destroyers and complex drug resistance modulators, as described below. It is performed by growing P-glycoprotein expressing complex drug resistant cell lines such as P388 VCR (Fredric NCI, DCT Repository, MD) and CHCR5 (Dr. Victor Ling, Vancouver, BC Cancer Agency, Vancouver, BC). MTT, {3- (4,5-dimethyl-thiazol-2-yl) -2,5-diphenyl tetrazolium bromide], DOX (doxorubicin), VP-16 (etoposide) and VLB (vinblastine) Sulfate) is commercially available from Sigma Chemical Co., St. Louis, Mo. Taxol (R) (paclitaxel from Bristol-Myers Oncology) is commercially available as ICN Biomedicals, Inc., Costa Mesa, CA. FBS (fetal bovine serum) is commercially available as Hyclone (Logan, UT). L-Glutamine and Minimum Essential Media for Suspension Cultures (SMEM) are commercially available from [GIBCO (Grand Island, NY)]. Tissue cultures with round bottom wells Seroclusters 96-well is commercially available from Costar, Cambridge, Mass. Tissue culture flasks are commercially available from Corning Glass Works, Corning, NY. Human leukemia cell line maternal CCRF-CEM and combination drug resistant CEM / VLB 100 (selected as 100 ng / ml vinblastine) were described by William T. Beck (Beck, WT, Mueller, MJ, and Tanzer LR, Altered Surface Membrane Glycoproteins in Vinca Alkaloid-Resistant Human Leukemic Lymphoblast, Cancer Research, 39, 2070-2076 (1979).] Cells are 10% FBS and 2 mM L in a wet incubator with 95% air and 5% CO 2. -Glutamine can be maintained in supplemented SMEM medium Cell number can be measured using Coulter Counter Model ZM Cells can be subcultured every 3-4 days. Cell viability is described by Denziot, F., Lang, R., "Rapid colorimetric assay for cell growth and survival modifications to the tetrazolium procedure giving improved sensitivity and reliability", J. Immunological Methods, 89, 271-277 , 1986). In this method cells are harvested during logarithmic growth phase and seeded in 96-well vertical cluster plates at 7.5 x 10 3 cells / well and serially diluted tumor cell disruptors (VLB, DOX, VP-16 and Taxol (R) ) ± modulators Incubated for 72 hours in the presence of. Single well analysis was performed using fixed concentrations (4 ng / ml) of VLB and regulator (5 μΜ). Cytotoxicity of the modulator alone was measured at the same concentration. Regulators were prepared as 2 mM stocks in DMSO and added to the wells to obtain a final concentration of 5 μM to 0.5 μM. After 72 hours 20 μl of freshly prepared MTT (5 mg / ml in Dulbecco's phosphate buffered saline pH 7.5) was added to each well and left for 4 hours in a 37 ° C. incubator. Cells were pelleted in a Sorvall RT6000B centrifuge for 10 minutes at 1800 RPM. After centrifugation, 70 μl of culture medium was carefully removed from each well and 100 μl of 2-propanol / 0.04N HCl was added to lyse blue formazan stained cells. Cells were resuspended in multiple pipettes 5-10 times or until particulate matter was not visible. Plates were immediately read on a Yitertek MCC / 340 microplate reader (Flow Laboratories, (McLean, VA), wavelength 570 nm and reference wavelength 630 nm). Controls were measured in modulators and 4-fold copies in copies. IC 50 was calculated from half-log dose response curves with and without modulators for maternal and resistant cell lines. Fold metastasis was calculated by dividing the IC 50 for cells treated with tumor cell destroyer alone by the IC 50 for cells treated with tumor cell destroyer and modulator. Taxol (R) was chosen as a test tumor cell disruptor for the studies described herein due to the high level of resistance of the cell line CEM / VLB 100 to Taxol (R) . IC 50 of Taxol (R) is aimed at achieving total reversible activity and is measured under changes in regulator concentration. Total reversible activity, or 100% reversible activity, is defined as the ability to achieve drug sensitivity in a complex drug-sensitive cell line corresponding to the sensitivity of the drug-sensitive maternal cell line. Such data is provided herein as Rev 50 and Rev 100 . This number is defined as the lowest concentration (μM) of modulator that can achieve 50% and 100% reversible activity, respectively. When an in vitro test for controlling drug resistance of an antimalarial drug is performed, the compound is evaluated for its ability to show drug resistance control when co-administered with the antimalarial drug. The test is performed by coordinating drug resistance modulators, drug resistant malaria species, and antimalarial drugs and evaluating drug resistant malaria species. Antimalarial drugs are drugs for which drug-resistant malaria species are known to be resistant. For example, malaria species. P. lopurae and blood. P. cynumolgi are all resistant to the antimalarial drug proguanyl. Modulator activity is defined as the ability to achieve drug sensitivity to antimalarial drugs in drug resistant malaria by combination administration of antimalarial drugs and selection of drug resistance modulators. Tests for reversible tjd of tj drug resistance to various malaria species are described in standard malaria references, for example, Chemotherapy of Malaria, Covell et al., 1995, World Health Organization, Geneva, and Practical Malariology, 2nd edition, Russell et al., 1963 , Oxford University Press. A simple screen test to determine the oral bioavailability of a drug is to test the presence of the drug or its metabolites in the blood using standard blood assay techniques after oral administration of the drug. The test is performed twice, once with the drug itself and twice with the presence of a drug resistance modulator. The results are compared to see how orally bioavailable the compound is in the presence of modulators. The test is not limited to humans but can be performed in any mammal. In vitro testing for the migration of compounds across the blood-brain barrier begins by growing a church monolayer of cerebellar endothelial or mouse brain capillary endothelial cells on a porous filter support to form a rigid endothelial cell layer. The method of obtaining malaria from one side of the vessel to the other side is to place the filter support in a phosphate buffered saline containing vessel such that it passes through the cell layer / porous filter support. Known compounds (eg mannitol) are placed in containers on the membrane surface of the cell layer / porous filter. Samples are removed from the spleen membrane surface of the cell layer / porous filter at intervals of 15 to 30 minutes over 3 to 6 hours. Standard analytical techniques are used to determine the amount of known compound in the sample. This information is used to calculate the baseline permeability of the cell layer / porous filter. The drug (eg, tumor cell destroyer or antimalarial agent) is then placed on one side of the same type of container containing freshly prepared saline and the cell layer / porous filter barrier. Samples are removed from the other side at 15-30 minute intervals over 3-6 hours. Standard analytical techniques are used to determine the amount of drug in the sample. The amount of the drug moving across the barrier is indicative of the baseline permeability of the cell layer / porous filter for that drug. The test is then repeated and in this case the drug and drug resistance modifier are placed on one side of the container prepared as above. Samples are collected and the test is performed as described above to observe how the drug moves across the cell layer / porous filter support, if a drug resistance modulator is present. An in vivo test to determine whether a drug administered to a mammal crosses the blood brain barrier is to test for the presence of the drug or its metabolites in the mammalian cerebrospinal fluid after the drug is administered to the mammal in any manner. . Such tests for determining whether a drug crosses the blood brain barrier, such as tests for oral bioavailability, are not limited to humans and can be performed in any mammal. The compounds of the present invention can be administered to any mammal. Of all mammals, humans are believed to be most advantageous due to the administration of these compounds. Compounds of formula (C) may be used in therapeutically effective amounts, for example (i) when administered in combination with a drug or therapeutic drug for a combination drug resistant disease, acts as a drug or combination drug resistance modulator, (ii) improve oral bioavailability of the drug, and / or (iii) is administered at a dosage sufficient to improve the bioavailability of the drug to the brain. Treatment of the disease (i) preventing disease, i.e. preventing the development of clinical symptoms of the disease, (ii) inhibit disease, i.e. stop the development of clinical symptoms, and / or (iii) alleviation of the disease, ie deterioration of clinical symptoms. Compounds of formula (C) are usually administered in combination during or after administration of the drug treating the disease. The preferred dosing schedule is a continuous infusion over the 24 hours in which the therapeutic drug is also administered. In cancer, the therapeutic drug may be a cancer chemotherapeutic agent, wherein paclitaxel, doxorubicin, adriamycin, etoposide, teniposide, vinblastine, vincristine, mycomycin C, daunorubicin and teniposide However, it is not limited thereto. Therapeutic drugs for malaria are antimalarial drugs and include but are not limited to Pharmaquine, Primaquine, Mepacrine, Doxycycline, Chloroquine, Amodiaquine, Quinine, Quinidine, Primethamine, Proguanil, Mefloquine and Sulfazin It is not limited. The daily dosage of a drug or combination drug resistance modulator for all the methods of treatment described herein ranges from about 100 mg / M 2 to about 1 g / M 2 of body surface area, preferably from about 200 mg / M 2 of body surface area to About 800 mg / M 2 , and most preferably about 400 mg / M 2 to about 500 mg / M 2 of body surface area. The number and amount of drugs or combination drug resistance modulator compounds administered are determined by the patient and the disease state to be treated, the extent of infection, the mode of administration and the schedule (eg, cancer chemotherapy per day compared to intravenous administration during cancer chemotherapy). Prior to oral administration) and diagnostic physician's judgment. The dose level of the disease treatment drug is determined with reference to the disease state, the diseased patient state and the disease treatment drug to be used. Standard medical references can be referenced to determine the extent of dosage for the disease treatment drugs described herein. The dose level of the disease treatment drug is also controlled for each receptor to minimize any undesirable side effects and to maximize the efficacy of the disease treatment drug. When a drug or combination drug resistance modulator is coadministered with the disease treatment drug, the dosage of the disease treatment drug may be the same or reduced depending on the efficacy of the drug or combination drug resistance modulator when performing its function. Any pharmaceutically acceptable mode of administration can be used when using a compound of the invention for the treatment of drug or combination drug resistance. The compound of formula (C) may be administered alone or in combination with other pharmaceutically acceptable excipients. Examples thereof include solid, semisolid and liquid dosage forms such as tablets, capsules, powders, solutions, suspensions, suppositories, and the like. In addition, suspended or controlled release dosage forms, including accumulative injections, osmotic pumps, pills, percutaneous (including electron transfer) ointments, and the like, for the prolonged administration of the compounds of the formula (C) at predetermined rates, preferably Can be administered in unit dosage forms suitable for single administration of a practical dosage. Compositions (also known as “formulations”) typically comprise conventional pharmaceutical carriers, diluents or excipients and compounds of formula (C). In addition, such compositions may include other therapeutic agents, pharmaceuticals, carriers, adjuvants, and the like. Depending on the therapeutic drug and the disease to be treated, the drug or combination drug resistance modulator may be administered in the same or different pharmaceutical compositions as the therapeutic drug. In general, depending on the intended dosage form, the pharmaceutically acceptable composition may contain from about 0.005% to about 95%, preferably from about 0.5% to about 50% by weight of the compound of formula (C), Are suitable pharmaceutical excipients, carriers and diluents. One mode of administration for the conditions described above is oral administration using a convenient daily dosing regimen that can be adjusted according to the extent of infection. For such oral administration, pharmaceutically acceptable non-toxic compositions include, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, sodium croscarmellose, glucose, gelatin, sucrose, magnesium carbonate and the like. As formed by the incorporation of any of the excipients conventionally used. Such compositions include solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations, and the like. Preferably the oral composition may be in the form of pills or tablets. Thus, the composition contains a diluent such as lactose, sucrose, dicalcium phosphate, etc., a lubricant such as magnesium stearate, and a binder such as starch, gum acacia, gelatin, polyvinylpyrrolidone, cellulose and derivatives thereof together with the active ingredient. something to do. Pharmaceutically administrable liquid compositions can be prepared by, for example, dissolving and dispersing any pharmaceutical adjuvant in an active compound as described above, and in a carrier such as, for example, water, saline, mannitol, aqueous dextrose, glycerol, glycol, ethanol, and the like. Can be prepared to form a solution or suspension. Pharmaceutical compositions to be administered if necessary also contain small amounts of wetting agents, emulsifiers or solubilizers, pH buffers and the like, for example acetates, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate and the like. May contain nontoxic auxiliary substances. Actual methods of preparing such dosage forms will be known or will be apparent to those skilled in the art, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 19th Edition, 1995. Parenteral administration is generally characterized by injection (eg, subcutaneously, intramuscularly, intravenously) or by infusion through the centerline. Injectables can be prepared in conventional forms, liquid solutions or suspensions, solid forms or emulsifiers suitable for solution or suspension in liquid prior to injection. Examples of suitable excipients are water, saline, dextrose, glycerol, ethanol, mannitol and the like. In addition, if desired, pharmaceutical compositions to be administered include small amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffers, solubility-improving agents and, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, cyclodextrin, etc. It may contain. Preferred liquid solutions for parenteral administration contain an appropriate amount of compound in a 5% solution of mannitol in water. More recently developed parenteral methods of administration use the insertion of slow release or sustained release systems to maintain a constant level of dosage. See US Pat. No. 3,710,795. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific properties thereof as well as the activity of the compound and the needs of the target. However, from about 0.01% to about 10% active ingredient percentage in solution is preferred, and will be higher if the composition to be subsequently diluted to that percentage is a solid. Preferably the parenteral composition will contain from about 0.2% to about 2% active agent in solution. A preferred mode of administration of the active ingredient is at present through infusion through the centerline. The following formulations and examples are provided to enable those skilled in the art to more clearly understand and to practice the present invention. This is not intended to limit the scope of the invention, but is intended to be illustrative only. The terms and abbreviations used in the examples have the usual meanings unless otherwise indicated. For example, "° C" represents degrees Celsius, "N" represents normal or normal degree, "mol" represents moles or moles, "mmol" represents millimoles or millimoles, and "g" represents grams or grams "Mg" represents milligrams or milliliters, "mp" represents melting point, "M" represents molarity, "psi" represents pounds per square inch, "KPa" "Stands for kilopascal," Mass Spec "stands for mass spectrometer," IR "stands for infrared spectrometer, and" NMR "stands for row magnetic resonance spectrometer. <Example 1a> 5-Indoquinoline A suspension of 10 g (0.07 mol) of 5-aminoquinoline, 94 ml (0.7 mol) of isoamylnitrite and 100 ml of diiodomethane was heated at 80 ° C. for 2 hours. The reaction mixture was evaporated at 60-70 ° C under reduced pressure. The residue was slurried with diethyl ether, discarded and the filtrate was evaporated under reduced pressure. The obtained residue was chromatographed on silica gel column eluting with 3: 1 hexane-ethyl acetate to give 2.81 g of 5-indoquinoline. 1 H-NMR (CDCl 3, 300 MHz) δ 7.42 (d, 1H, J = 7.7 Hz); 7.48 (dd, 1H, J = 4.3 Hz); 8.1 (m, 2 H,); 8.38 (d, 1 H, J = 8.5 Hz); 8.88 (m, 1 H). Mass spec. m / e = 255 = p. <Example 1b> 5-quinoline- [1-propioaldehyde diethyl acetal] 2.18 g (0.022 mol) of triethylamine were added to a suspension of 2.75 g (0.011 mol) of 5-indoquinoline in 24 ml of acetonitrile and the solution formed with warming. The solution was cooled quickly. To the solution was added 50 mg of triphenylphosphine, 50 mg of palladium (II) acetate and 3.1 mL (0.022 mol) of 3,3-diethoxy-1-propyne (propioaldehyde diethylacetal). The reaction was heated at 80 ° C for 1.5 h. The reaction was poured into water and extracted with hexanes. Hexanes were removed under reduced pressure and the residue was chromatographed on silica gel column with 1% methanol-dichloromethane and chromatographed to give 1.44 g of 5-quinoline- [1-propioaldehyde diethyl acetal]. 1 H-NMR (CDCl 3, 300 MHz) δ 1.3 (t, 6H, J = 7.2 Hz); 3.73 (m, 2 H,); 3.88 (m, 2 H); 5.62 (s, 1 H,); 7.48 (dd, 1H, J = 8.5 and 4.2 Hz0; 7.66 (d, 1H, J = 7.4 Hz); 7.76 (d, 1H, J = 7.2 Hz); 8.1 (d, 1H, J = 8.5 Hz); 8.6 (d, 1H, J = 8.5 Hz 0; 8.94 (m, 1 H)) Mass spectrometry m / e = 255 = p. <Example 1c> 5-quinoline- [1-propionaldehyde] A mixture of 0.15 g of 5-quinoline- [1-propioaldehyde diethyl acetal] in 10 ml of ethanol and 0.035 g of 10% palladium on carbon was hydrogenated at 45 psi (310 KPa) for 1.5 hours. The catalyst was removed by filtration and the solvent was removed under reduced pressure. The residue was dissolved in 1 ml of 1.0 N HCl and 10 ml of tetrahydrofuran and stirred at room temperature for 2 hours to convert the acetal to an aldehyde functional group. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate and washed with sodium bicarbonate solution. The solvent was removed under reduced pressure to give 63 mg of 5-quinoline- [1-propionaldehyde]. 1 H-NMR (CDCl 3, 300 MHz) δ 2.95 (t, 2H, J = 7.4 Hz); 3.43 (t, 2H, J = 7.4 Hz); 7.44 (m, 2 H); 7.66 (t, 1 H, J = 7.4 Hz); 8.0 (d, 1 H, J = 8.5 Hz); 8.33 (d, 1 H, J = 8.5 Hz); 8.94 (m, 1 H); 9.9 (s, 1 H). Mass spectrometry m / e = 186 = p. <Example 1d> 5- (3,4-epoxybut-1-yl) quinoline To a suspension of 0.47 g (2.1 mmol) of trimethyl-sulfoxium iodide in 5 ml of dimethylsulfoxide was added 85 mg (2.1 mmol) of 60% sodium hydride. After 30 minutes a solution of 0.33 g (1.93 mmol) of 5-quinoline- [1-propion-aldehyde] in 7 ml of dimethylsulfoxide was added. After 30 minutes the reaction was poured into cold brine and extracted with ethyl acetate. The organic layer was dried, the solvent was removed under reduced pressure and the residue was eluted with 50% ethyl acetate-hexane on a silica gel column and chromatographed to give 40 mg of 5- (3,4-epoxybut-1-yl) quinoline. 1 H-NMR (CDCl 3, 300 MHz) δ 1.87 (m, 2H); 2.5 (m, 1 H); 3.03 (m, H); 3.24 (m, 2 H,); 7.44 (m, 2 H); 7.65 (t, 1 H, J = 7.4 Hz); 8.0 (d, 1 H, J = 8.5 Hz); 8.4 (d, 1 H, J = 8.5 Hz); 8.94 (d, 1H, J = 4.2 Hz) mass spectrometry m / e = 199 = p. <Example 1e> Anti-5- {1- [4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl] -2 (R, S) -hydroxybut-4- Quinoline, 3HCl 31 mg (0.16 mmol) of 5- (3,4-epoxybut-1-yl) quinoline in 1.5 ml of isopropyl alcohol and 4-N- (1 '-(10,11-difluorocyclopropyldibenzosuber) A solution of 51 mg (0.16 mmol) of piperazine (obtained using the method described in PCT patent application PCT / US94 / 04215, publication number WO 94/24107) was refluxed for 4.5 hours. The residue was removed under reduced pressure and chromatographed on a silica gel column eluting with ethyl acetate followed by 5% methanol-dichloromethane The residue was dissolved in 3 ml of ethyl alcohol, cooled and treated with anhydrous hydrogen chloride gas. Evaporated under anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S) -hydroxybutyrate 43 mg of a mixture of -4-yl} quinoline and 3HCl were obtained: Fusion 160-170 ° C. Dec. 1 H-NMR (CDCl 3, 300 MHz) (free base) δ 1.78 (m, 2H); 2.5 (m, 10H) ; 3.19 (d, 2H, J = 12.4 Hz); 3.19 (m, 1H), 3.37 (m, 1H); 3.75 (m, 1H); 3.93 (s, 1H); 7.2 (m, 8H); 7.44 ( dd, 1H, J = 8.5 and 4.2 Hz); 7.63 (t, 1H, J = 7.4 Hz); 7.97 (d, 1H, J = 8.5 Hz); 8.45 (d, 1H, J = 8.5 Hz); 8.9 ( m, 1H) Mass spectrometry m / e = 525 = p. <Example 2a> (S) -5- (glycidyl) -thioquinoline To a solution of 0.13 g (0.51 mmol) of 5-iodoquinoline in 4 mL of tetrahydrofuran was added 0.59 mL (1.0 mmol) of t-butyllithium (1.7 M in hexane) at -78 ° C. After 10 minutes 20 mg (0.61 mmol) of sulfur was added and the coolant was removed. After 40 minutes the reaction was cooled to 5 ° C. and 0.132 g (0.51 mmol) of (2R)-(−)-glycidyl 3-nitrobenzenesulfonate were added. After 30 minutes the reaction was poured into cold brine, extracted with ethyl acetate and concentrated to an orange residue under reduced pressure. The residue was chromatographed on silica gel column, eluting with 2% methanol-dichloromethane to give 27 mg of (S) -5- (glycidyl) -thioquinoline. 1 H-NMR (CDCl 3, 300 MHz) δ 2.41 (m, 1H); 2.72 (m, 1 H); 3.02 (t, 1 H, J = 4.4 Hz); 3.16 (m, 2 H); 7.45 (dd, 1H, J = 8.5 and 4.2 Hz); 7.65 (m, 2 H); 8.05 8.93 (m, 1 H). Mass spectrometry m / e = 217 = p. <Example 2b> Anti-5- {1- [4- (10,11-difluorocyclopropyldibenzosuber-5-yl) -piperazin-1-yl] -2 (R) -hydroxyprop-3- Ilthio} quinoline3HCl 25 mg (0.12 mmol) of (S) -5- (glycidyl) -thioquinoline in 2 ml of isopropyl alcohol and 4-N- (1 ′-(10,11-difluorocyclopropyldibenzosuber-) 5-day) A mixture of piperazine 38 mg (0.12 mmol) (obtained using the method described in PCT patent application PCT / US94 / 04215, publication number WO 94/2407) was refluxed for 3 hours and then the solvent was depressurized Removed and the residue was eluted with 2-3% methanol in dichloromethane on a silica gel column and chromatographed to give anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5 39 mg of -yl) piperazin-1-yl) -2 (R) -hydroxyprop-3-ylthio} quinoline 3HCl mp 125-130 ° C. dec; 1 H-NMR (CDCl 3, 300 MHz) ) δ 2.45 (m, 10H); 3.05 (m, 2H); 3.16 (d, 2H, J = 12.4 Hz); 3.86 (m, 1H); 3.9 (s, 1H); 7.2 (m, 8H); 7.45 (dd, 1H, J = 8.5 and 4.2 Hz); 7., 65 (m, 2H); 8.0 (d, 1H, J = 8.0 Hz); 8.75 (d, 1H, J = 8.7 Hz); 8.93 (m Mass spectrometry m / e = 543 = p. Analysis: C, 70.70; H, 5.75; N, 7.73; S, 5.90 Found analysis:. C, 69.98; H, 5.78; N, 7.34; S, 5.65. <Example 3> Compounds of Example 1e (anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-yl} quinoline 3HCl and the compound of Example 2b (anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin- 1-yl) -2 (R) -hydroxyprop-3-ylthio} quinoline.3HCl all exhibited potential MDR reversible activity in the p-glycoprotein MDR assay described above with Taxol (R) . ExampleRev 100 (μM)Rev 50 (μM) 1e〉 1.01.0 2b0.500.25 Compare * 0.100.050* Comparative Example is anti-5- {1- (number-cyclopropyl-4-dibenzo (10,11-difluoro-Bell-5-yl) piperazin-1-yl) -2 (R) - hydroxypropoxy P-3-oxy} quinoline. The following formulation examples are for illustrative purposes only and are not intended to limit the scope of the invention. An "active ingredient" is a compound of formula (C) or a pharmaceutically acceptable salt or solvate thereof. <The first time> Hard gelatin capsules were prepared using the following ingredients. Amount (mg / capsules) Active ingredient 250 Dry starch 200 Magnesium Stearate 10 460 mg total <Optimum 2> Tablets were made using the following ingredients. Amount (mg / capsules) Active ingredient 250 Microcrystalline Cellulose 400 Fumigation Silicon Dioxide 10 Stearic acid 5 665 mg total The components were combined and pressed to form 665 mg tablets. <The third> Tablets containing 60 mg of each active ingredient were prepared as follows. Amount (mg / tablet) Active ingredient 60 Starch 45 Microcrystalline Cellulose 35 Polyvinylpyrrolidone (10% solution in water) 4 Sodium carboxymethyl starch 4.5 Magnesium Stearate 0.5 Talc 1 Total 150 The active ingredient, starch and cellulose were transferred to Mesh 45 U.S. Pass through the sieve and mix thoroughly. Polyvinylpyrrolidone-containing aqueous solution was mixed with the obtained powder, and the mixture was mixed with Mesh 14 U.S. Passed the sieve. The granules thus produced were dried at 50 ° C. and subjected to Mesh No. 18 U.S. Passed the sieve. Sodium Carboxymethyl Starch, Magnesium Stearate and Talc were prepared in advance using No. 60 Mesh U.S. After passing through the sieve, it was added to the granules, mixed, and pressed on a tablet machine to obtain tablets of 150 mg each. 〈Title 4〉 Capsules containing 80 mg of active ingredient were prepared as follows. Amount (mg / capsules) Active ingredients 80 Starch 59 Microcrystalline Cellulose 59 Magnesium Stearate 2 200 total The active ingredient, cellulose, starch and magnesium stearate were blended and mesh 45. U.S. Pass through the sieves and fill in an amount of 200 mg in hard gelatin capsules. <Opposition 5> Suppositories containing 225 mg of the active ingredient were prepared as follows. Amount (mg / unit) Active ingredient 225 Saturated Fatty Acid Glyceride 2000 Total 2225 The active ingredient was prepared using Mesh 60 U.S. Pass through the sieve and suspend in pre-melted saturated fatty acid glycerides using the minimum heat required. The mixture was then poured into a 2 g suppository mold and cooled. <Title 6> Suspending agents containing 50 mg of each active ingredient per 5 ml of dose were prepared as follows. amount Active ingredient (s) 50 mg Sodium Carboxymethyl Cellulose 50mg Syrup 1.25 ml 0.10 ml benzoic acid solution Spice fitness bulk Colorant fitness bulk 5 ml of purified water The active ingredient is prepared using Mesh 45 U.S. The paste was prepared by passing through a sieve and mixing with sodium carboxymethyl cellulose and syrup. The benzoic acid solution, flavor and colorant were diluted with water and added with stirring. Sufficient water was then added to produce the desired volume. <The seventh> Intravenous formulations can be prepared as follows. amount 100 mg active ingredient 1000 ml of isotonic saline
权利要求:
Claims (24) [1" claim-type="Currently amended] A compound of formula (C): and a pharmaceutically acceptable salt or solvent compound thereof. <Formula C> In the formula, R 1 and R 2 are independently hydrogen or halo, A is -CH 2 -CH 2 -or CH 2 -CHR 4- (CH 2 ) n (here, n is 1 or 2, R 4 is -H, -OH or -R 5 , -R 5 is or ego, -R 6 is C 1 -C 6 alkyl or ego, m is 1, 2, 3, 4, 5 or 6, R 7 is —H or C 1 -C 6 alkyl) When A is CH 2 -CHR 4- (CH 2 ) n , A and Z are arranged as CH 2 -CHR 4- (CH 2 ) n -Z, Z is selected from the group consisting of -S-, -S (O) w -and -CH 2- , wherein w is 1 or 2, R 3 is aryl being jangiyi selected from the group consisting of phenyl, substituted phenyl, heteroaryl, substituted heteroaryl, polynuclear aryl and substituted polynuclear aryl, with the proviso that Z is connected to the R 3 ring carbon atoms in the R 3. [2" claim-type="Currently amended] The compound of claim 1, wherein both R 1 and R 2 are halo, and R 3 is quinolyl, substituted quinolyl, isoquinolyl, substituted isoquinolyl, indolyl, substituted indolyl, naphthyl, substituted Is selected from the group consisting of naphthyl, A is CH 2 -CHR 4- (CH 2 ) n , wherein R 4 is -OH and n is 1 or 2, and Z is -S- or -CH 2 Phosphorus compounds. [3" claim-type="Currently amended] The method of claim 1, 1a) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-yl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1b) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-yl} quinoline or Pharmaceutically acceptable salt or solvent compounds thereof; 1c) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) pent-5-yl} quinoline or Pharmaceutically acceptable salt or solvent compounds thereof; 1d) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylthio} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1e) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylthio} Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1f) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylthio} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1 g) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfinyl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1h) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfinyl} Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1i) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfinyl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1j) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfonyl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1k) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfonyl} Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1l) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfonyl} quinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 1 m) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1n) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxypent-5yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1o) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylthio} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1p) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylthio} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1q) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfinyl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1r) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfinyl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1s) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfonyl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1t) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfonyl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1u) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) but-4yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1v) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) pent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1w) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) but-4-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1x) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) pent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1y) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) but-4-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1z) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1aa) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxybut-4-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1bb) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxypent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1 cc) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carboxybut-4-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 1dd) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2a) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-yl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2b) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-yl} isoquinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 2c) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) pent-5-yl} isoquinoline Or a pharmaceutically acceptable salt or solvent compound thereof; 2d) (thin, -anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylthio} Isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2e) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylthio} Isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2f) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylthio} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2 g) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfinyl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2h) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfinyl} Isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2i) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfinyl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2j) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfonyl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2k) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfonyl} Isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 21) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfonyl} iso Quinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2m) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2n) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxypent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2o) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylthio} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2p) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylthio} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2q) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfinyl} -isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2r) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfinyl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2s) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfonyl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2t) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfonyl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2u) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) but-4yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2v) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) pent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2w) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) but-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2x) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) pent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2y) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) but-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2z) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2aa) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxybut-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2bb) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S) oxy Carbonyloxy (C 1 -C 6 alkanediyl) carboxypent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2 cc) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carboxybut-4-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 2dd) (thin, anti) -5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} isoquinoline or a pharmaceutically acceptable salt or solvent compound thereof; 3a) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-yl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3b) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-yl} indole or Pharmaceutically acceptable salt or solvent compounds thereof; 3c) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) pent-5-yl} indole or Pharmaceutically acceptable salt or solvent compounds thereof; 3d) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylthio} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3e) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylthio} Indole or a pharmaceutically acceptable salt or solvent compound thereof; 3f) (thin, anti) -4- {1-4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylthio} indole or Pharmaceutically acceptable salt or solvent compounds thereof; 3 g) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfinyl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3h) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfinyl} Indole or a pharmaceutically acceptable salt or solvent compound thereof; 3i) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfinyl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3j) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfonyl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3k) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfonyl} Indole or a pharmaceutically acceptable salt or solvent compound thereof; 31) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfonyl} indole Or a pharmaceutically acceptable salt or solvent compound thereof; 3m) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3n) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxypent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3o) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylthio} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3p) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylthio} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3q) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfinyl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3r) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfinyl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3s) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfonyl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3t) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfonyl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3u) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) but-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3v) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) pent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3w) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) but-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3x) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) pent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3y) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) but-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3z) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3aa) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxybut-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3bb) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxypent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3 cc) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carboxybut-4-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 3dd) (thin, anti) -4- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} indole or a pharmaceutically acceptable salt or solvent compound thereof; 4a) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-yl} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4b) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-yl} naphthalene or Pharmaceutically acceptable salt or solvent compounds thereof; 4c) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) pent-5-yl} naphthalene or Pharmaceutically acceptable salt or solvent compounds thereof; 4d) (thin, -anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylthio} Naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4e) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylthio} Naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4f) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylthio} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4 g) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfinyl} nat Talene or a pharmaceutically acceptable salt or solvent compound thereof; 4h) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfinyl} Naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4i) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfinyl} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4j) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) eth-2-ylsulfonyl} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4k) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) prop-3-ylsulfonyl} Naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 41) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) but-4-ylsulfonyl} naphthalene Or a pharmaceutically acceptable salt or solvent compound thereof; 4m) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4n) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxypent-5yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4o) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylthio} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4p) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylthio} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4q) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfinyl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4r) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfinyl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4s) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxyprop-3-ylsulfonyl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4t) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-ylsulfonyl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4u) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) but-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4v) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxy (C 1 -C 6 alkanoyl) pent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4w) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) but-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4x) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanoxy) pent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4y) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) but-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4z) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4aa) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxybut-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4bb) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyloxy (C 1 -C 6 alkanediyl) carboxypent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4 cc) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carboxybut-4-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof; 4dd) (thin, anti) -1- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Oxycarbonyl (C 1 -C 6 alkanediyl) carbonyl (C 1 -C 6 alkanoxy) pent-5-yl} naphthalene or a pharmaceutically acceptable salt or solvent compound thereof, and mixtures thereof Selected compound. [4" claim-type="Currently amended] The compound according to claim 1, wherein the anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R, S)- Hydroxybut-4-yl} quinoline, or a pharmaceutically acceptable salt or solvent compound thereof. [5" claim-type="Currently amended] Trihydrochloride salt of the compound of claim 4. [6" claim-type="Currently amended] The compound of claim 1, wherein the anti-5- {1- (4- (10,11-difluorocyclopropyldibenzosuber-5-yl) piperazin-1-yl) -2 (R) -hydroxy Prop-3-ylthio} quinoline or a pharmaceutically acceptable salt or solvent compound thereof. [7" claim-type="Currently amended] Trihydrochloride salt of the compound of claim 6. [8" claim-type="Currently amended] A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient together with the compound of claim 1 or a salt or solvent compound thereof. [9" claim-type="Currently amended] The pharmaceutical composition of claim 8, further comprising a cancer treatment drug. [10" claim-type="Currently amended] The pharmaceutical composition of claim 8, further comprising a malaria therapeutic drug. [11" claim-type="Currently amended] A method of treating a drug resistant disease comprising administering a resistance modulated amount of a compound of claim 1, or a salt or a solvent compound thereof, and an effective amount of a drug resistant disease to a mammal in need thereof. [12" claim-type="Currently amended] A method of treating a compound drug resistant disease, comprising administering a drug with a controlled dose of the compound of claim 1, or a salt or a solvent compound thereof, and an effective amount of the drug in a mammal in need thereof. [13" claim-type="Currently amended] The method of claim 11, wherein the drug resistance is caused by P-glycoprotein action. [14" claim-type="Currently amended] The method of claim 11, wherein the drug resistant disease is cancer and the therapeutic drug is cancer chemotherapy drug (s). [15" claim-type="Currently amended] The method of claim 11, wherein the drug resistant disease is malaria and the therapeutic drug is antimalarial drug (s). [16" claim-type="Currently amended] The method of claim 12, wherein the combination drug resistant disease is cancer and the therapeutic drug is cancer chemotherapy drug (s). [17" claim-type="Currently amended] A therapeutically effective amount of a drug, and an amount of the compound of claim 1, or a salt or solvate thereof, sufficient to allow the drug to enter the brain through the blood brain barrier; Method of enhancing the bioavailability of the drug. [18" claim-type="Currently amended] A therapeutically effective amount of a drug, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a drug and an amount of the compound of claim 1 or a salt or solvent thereof, sufficient to allow the drug to enter the bloodstream through the gastrointestinal tract. Methods of Enhancing Oral Bioavailability. [19" claim-type="Currently amended] Use of the compound of claim 1, or a salt or a solvent compound thereof, and an effective amount of a therapeutic drug in the manufacture of a medicament for treating a drug resistant disease. [20" claim-type="Currently amended] Use of a compound of claim 1, or a salt or a solvent thereof, and an effective amount of a therapeutic drug in the manufacture of a medicament for the treatment of a combination drug resistant disease. [21" claim-type="Currently amended] 20. The use of claim 19, wherein the drug resistance is caused by P-glycoprotein action. [22" claim-type="Currently amended] The method of claim 19, wherein the drug resistant disease is cancer and the therapeutic drug is cancer chemotherapeutic drug (s). [23" claim-type="Currently amended] The method of claim 19, wherein the drug resistant disease is malaria and the therapeutic drug is antimalarial drug (s). [24" claim-type="Currently amended] The method of claim 20, wherein the combination drug resistant disease is cancer and the therapeutic drug is cancer chemotherapy drug (s).
类似技术:
公开号 | 公开日 | 专利标题 US20180002289A1|2018-01-04|Malate salt of N-|-N'-|cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer US20170182037A1|2017-06-29|Polymorphic forms of 1-[4-|butyl]-4-| piperazine hydrochloride US10137118B2|2018-11-27|Crystalline polymorphs of the free base of 2-hydroxy-6-|pyridin-3-yl)methoxy)benzaldehyde US8716497B2|2014-05-06|Method for enantioselective hydrogenation of chromenes JP2018123154A|2018-08-09|Ivabradine hydrochloride form iv CN101780092B|2012-07-04|Compounds and methods for delivery of prostacyclin analogs KR910009199B1|1991-11-04|Novel heterocyclic compounds and anticancer drug reinforcing agents containign effective component DK1720853T3|2016-03-29|His unknown polymorph form of imatinibmylylate and procedure for preparing it US6730326B2|2004-05-04|Thermodynamically stable modification of 1-|-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it TWI272267B|2007-02-01|Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors TW199153B|1993-02-01| US6441193B1|2002-08-27|Estrogen agonists/antagonists US7026320B2|2006-04-11|Serotonergic agents JP2996708B2|2000-01-11|Heterocyclic derivatives, process for producing the same, and pharmacological composition containing the derivative for use in treatment of leucotriene-induced disease or symptom JP3760264B2|2006-03-29|Aripiprazole hydrate, aripiprazole anhydrous crystals, methods for producing them and formulations containing them US6063812A|2000-05-16|Fumagillol derivatives and processes for preparing the same EP0902013B1|2001-12-12|Novel amidine derivatives, their preparation and their use as medicaments with LTB-4 antagonistic effect KR101761380B1|2017-07-25|Methods of using c-met modulators KR100357541B1|2002-10-18|5-Demthoxyfumagillol derivatives and processes for preparing the same ES2374922T3|2012-02-23|Aripiprazol crystal forms preparation procedures. KR100195070B1|1999-06-15|Quinolone carboxylic acid derivatives KR100554988B1|2006-02-24|2-Amino-Nicotinamide Derivatives and Their Use as VEGF-Receptor Tyrosine Kinase Inhibitors JP3150155B2|2001-03-26|Compounds having both potent calcium antagonistic and antioxidant activities and their use as cytoprotective agents JP2007523896A|2007-08-23|Crystal form of ascomycin and its preparation method JP2007526251A|2007-09-13|Ezetimibe polymorph
同族专利:
公开号 | 公开日 EP0844244A1|1998-05-27| HU9904273A2|2000-05-28| JP2001504481A|2001-04-03| HU9904273A3|2001-01-29| BR9713401A|2000-01-25| AU3485797A|1998-06-10| CA2272390A1|1998-05-28| WO1998022112A1|1998-05-28| IL130055D0|2000-02-29|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题
法律状态:
1996-11-22|Priority to US3172696P 1996-11-22|Priority to US60/031,726 1997-06-12|Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 2000-09-15|Publication of KR20000057157A
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US3172696P| true| 1996-11-22|1996-11-22| US60/031,726|1996-11-22| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|